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Abstract 
Tumor growth and metastasis are dependent on neovascularization, which is mainly accomplished by the process 
of angiogenesis-sprouting of new microvessels from the existing blood vessels. To gain its ability of growth and 
invasiveness, malignant cells often express high levels of angiogenic factors that stimulate tumor angiogenesis 
and remodel tumor vessels. In addition to malignant cells, other host cells in the tumor microenvironment, 
including inflammatory cells, stromal fibroblasts and perivascular cells also significantly contribute to 
production of angiogenic factors and cytokines. Co-existence of various angiogenic factors and cytokines will 
inevitably cause interplay of various signaling pathways, leading to synergistic effects of tumor angiogenesis. 
Thus, therapeutic development of angiogenic factor inhibitors should be aimed to block not only the vertical 
signaling pathway triggered by a specific factor, but the horizontal interplay of various angiogenic pathways. 
This review discusses the mechanisms that underlie tumor angiogenesis, provides a few examples of angiogenic 
pathways that are commonly seen in most tumor types, and discusses the challenges of antiangiogenic cancer 
therapy. 
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Discovery of tumor angiogenic 
factors 
In 1971, Judah Folkman, in his hypothetical and 
conceptual article, proposed that tumors produce 
angiogenic factors and inhibition of tumor 
angiogenesis would offer a new therapeutic option 
for treatment of cancer (Folkman, 1971). Based on 
this hypothesis, extensive research was initiated 
during early research for identification of tumor-
derived-angiogenic factors and accumulating 
evidence supported the existence of tumor 
angiogenic factors although their identities 
remained unknown at that time (Folkman et al., 
1971; Langer et al., 1976). The first angiogenic 
factor was isolated from the pituitary of mammals 
(Gospodarowicz, 1976). In 1984, Folkman and 
colleagues isolated the first tumor angiogenic 
factor, i.e., basic fibroblast growth factor (bFGF or 
FGF-2), from a chondrosarcoma, and thus 
validating the concept that tumors produce 
angiogenic factors to induce neovascularization 
(Shing et al., 1984). Simultaneous to identification 
of tumor angiogenic factors, Dvorak and colleagues 
identified a potent vascular permeability factor 
(VPF) from tumor cells (Senger et al., 1983). These 
initial findings demonstrated that tumor-derived 
angiogenenic factors are able to stimulate 
angiogenesis and to modulate vascular structures. 
The same VPF, clones sequenced by Connolly and 
colleagues, was found to be structurally related to 
platelet-derived growth factor (Keck et al., 1989). 
In the same issue of Science magazine, Dr. 
Napoleone Ferrara and colleagues published their 
findings on identification of vascular endothelial 
growth factor (VEGF) as a potent angiogenic 
factor, which sequence identity with VPF (Leung et 
al., 1989). These initial findings paved new avenues 
for subsequent identification and cloning of 
numerous other angiogenic factors related to tumor 
growth and invasion, including those members in 
the VEGF, FGF, PDGF, angiopoietin, and notch 
ligand families. 
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Tumor microenvironment and the 
switch to an angiogenic 
phenotype 
Genetic instability of malignant cells often leads to 
accumulation of mutations of oncogenes and tumor 
suppressor genes and these mutated oncogenic 
proteins often upregulate expression levels of 
angiogenic factors (Cao et al., 2009). The fact that 
tumor tissues contain heterogenic populations of 
malignant cells implies that various tumor cells 
even in the same tumor mass would produce 
different levels of angiogeneic factors. Although the 
clinical significance of highly angiogenic tumor 
cells in tumor growth and invasion is not fully 
understood, it is reasonably speculated that the 
highly angiogenic tumor cell population might 
eventually dominate the entire tumor mass owing to 
their growth advantages. In contrast to tumor cells, 
somatic cells in healthy adult tissues may only 
produce modest levels of proangiogenic factors, 
which are not able to induce an angiogenic 
phenotype. Additionally, endogenous angiogenesis 
inhibitors are predominately expressed at high 
levels to prevent excessive neovascularization (Cao, 
2008). Thus, angiogenesis rarely occurs in healthy 
adult tissues, except in the reproductive organs and 
tissue regeneration. To create an angiogenic 
phenotype, tumors have to tip the balance of 
angiogenic factors over inhibitors (Figure 1). Other 
cell types in the tumor microenvironment including  
inflammatory cells and stromal fibroblasts are also 
significant sources of tumor angiogenic factors and 
they significantly contribute to the switch of tumor 
angiogenesis (Figure 1). 
Angiogenic signaling pathways 
Since identification of VEGF and FGF-2 as potent 
angiogenic factors in 1980s, numerous angiogenic 
pathways have been discovered and their specific 
roles in regulation of tumor angiogenesis and 
vascular remodeling have been defined. Most 
angiogenic factors trigger angiogenic signals 
through specific interaction with their cell surface 
receptors that often contain tyrosine kinase domains 
in endothelial cells.  
In general, various angiogenic factors appear to 
have distinct functions in regulation of vessel 
growth, vascular permeability and remodeling. 
VEGF is a potent angiogenic and vascular 
permeability factor that induces vascular sprouting 
and vascular leakiness (Leung et al., 1989; Senger 
et al., 1983). The Dll4-Notch signaling system 
prevents excessive vascular sprouting from the 
"stalk region" of blood vessels (Noguera-Troise et 
al., 2006; Ridgway et al., 2006) (Figure 2). The 
PDGF-BB-PDGFR-β signaling in perivascular cells 
such as pericytes mediates recruitment of these 
mural cells onto the newly formed vasculatures 
(Lindahl et al., 1997). These distinctive functions 
can be divided even within the same family 
angiogenic factors. For example, Ang1 and Ang2 
within the angiopoietin family seem to display 
opposing effects on vascular remodeling even 
though they bind to the same endothelial Tie2 
receptor (Maisonpierre et al., 1997). 
 
Figure 1. Angiogenic switch in tumor tissues. Tumor cells together with other host cells including inflammatory cells and 
stromal fibroblasts produce high levels of proangiogenic factors and reduced levels of endogenous inhibitors, tipping the balance 
towards a proangiogenic phenotype. 
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Figure 2. Angiogenic regulators that control the precise steps of new vessel growth. VEGF is a driving force that induces 
tip cell formation through activation of VEGFR2 signaling. Angiogenic endothelial cells produce PDGF-BB to recruit pericytes 
onto newly formed vessels to prevent excessive sprouting. The Dll4-Notch1 signaling also prevent excessive vascular sprouting 
from "stalk cells". 
 
Thus, angiogenic factors whether within the same 
family or in different families have distinctive roles 
in modulation of vessel growth and remodeling. 
During tumor angiogenesis, these signaling 
pathways may become uncoordinated, leading to 
the formation of disorganized and primitive 
vascular networks. 
Interplay between angiogenic 
factors 
Co-existence of various angiogenic factors, 
cytokines, signaling receptors and intracellular 
signaling components often results in crosstalk 
between various signaling pathways. Thus, in tumor 
tissues various angiogenic factors and cytokines not 
only transduce their signals vertically, but also 
interact each other horizontally. At the ligand level, 
various angiogenic factors with the same family can 
interact each other. For example, VEGF-A and 
PlGF or VEGF-B can form heterodimers in 
addition to their respective homodimers and 
heterodimers may different biological functions 
(Cao et al., 1996; Olofsson et al., 1996). Similarly, 
PDGF-A and PDGF-B can also form heterodimers 
that display overlapping but yet different functions 
from their corresponding homodimers (Heldin and 
Westermark, 1989b). The same heterodimerization 
mechanism also exists in various VEGF receptor 
molecules and PDGF receptor molecules (Heldin 
and Westermark, 1989a; Mac Gabhann and Popel, 
2007). Similarly, interactions between cell surface 
receptors beyond the same family also exist, 
demonstrating the complex signaling transduction 
of these receptors. Activation of a particular 
signaling pathway often induces and amplifies 
signaling pathways. For example, stimulation of 
endothelial cells and angiogenesis by FGF-2 
induces expression levels of PDGFR expression, 
and thus triggering a synergistic angiogenic 
response (Cao et al., 2003). Such a synergistic 
angiogenic activity in the tumor microenvironment 
promotes tumor growth, invasion and metastasis 
(Nissen et al., 2007). Therefore, assessment of 
angiogenic profiles in a given tumor tissue should 
consider potential interaction relations between 
various angiogenic factors and signaling pathways. 
Targeting angiogenic pathways 
in tumors 
The original idea of blocking tumor-derived 
angiogenic factors for cancer therapy was raised by 
Dr. Judah Folkman. In his conceptual paper, 
Folkman wrote "One approach to the initiation of 
'anti-angiogenesis' would be the production of an 
antibody against tumor angiogenic 
factor"(Folkman, 1971). His prediction and vision 
were validated in human cancer patients 33 years 
later with approval of bevacizumab, an anti-VEGF 
neutralizing antibody, by US FDA in 2004 for 
treatment of human colorectal cancer (Hurwitz et 
al., 2004). In fact, bevacizumab remains as the most 
commonly used antiangiogenic drugs for treatment 
of various human cancers either in combination 
with chemotherapy or monotherapy settings. 
Antiangiogenic drugs that block signaling pathways 
can be divided into several categories according to 
their targets and specificity: 1) Inhibition of 
angiogenic factor production from various cell 
types of tumors. These may include inhibition of 
transcription and translation of a specific 
angiogenic factor; 2) Functional neutralization of 
angiogenic factors. Bevacizumab targeting VEGF is 
one of such neutralizing antibodies (Hurwitz et al., 
2004); 3) Anti-receptor neutralizing antibodies. 
Similar to angiogenic ligands, binding of antibodies 
to specific regions of extracellular domains of a 
receptor could also effectively block their ligand-
triggered angiogenic signaling. Ramucizumab, an 
anti-VEGFR2 neutralizing antibody is an example 
of such drugs that are under clinical development 
(Fuchs et al., 2014); 4) Tyrosine kinase inhibitors 
(TKIs) that block angiogenic receptor functions. 
There are 7 currently US-FDA-approved 
antiangiogenic TKIs, including: axitinib, 
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cabozantinib, pazopanib, regorafenib, sorafenib, 
sunitinib, and vandetanib (Choueiri et al., 2012; 
Cohen et al., 2008; Escudier et al., 2007; George et 
al., 2012; Houvras and Wirth, 2011; Motzer et al., 
2013; Motzer et al., 2007). In general, TKIs lacks 
specificity and each TKI blocks the activity of 
several tyrosine kinases. The antiangiogenic TKIs 
share overlapping, but yet target different spectrums 
of angiogenic pathways. VEGFR2, as a key 
functional receptor for VEGF-induced 
angiogenesis, is one of the common targets of these 
TKIs. TKIs have been clinically used for treatment 
of various human cancers; 5) Inhibition of 
downstream signaling components. For example, 
mTOR (mammalian targets of rapamycin) 
inhibitors including temsirolimus and everolimus 
potently suppress tumor angiogenesis (Fazio et al., 
2007; Yao et al., 2011); 6) Generic angiogenesis 
inhibitors. Thalidomide is an example of generic 
angiogenesis inhibitor that blocks a common 
pathway of angiogenesis that is currently used for 
treatment of multiple myeloma (Singhal et al., 
1999); 7) Endogenous angiogenesis inhibitors. 
These inhibitors such as angiostatin and endostatin 
exhibit a broad-spectrum inhibitory activity against 
tumor angiogenesis induced by various stimuli 
(O'Reilly et al., 1997; O'Reilly et al., 1994). A 
variant version of endostatin has been approved by 
the Chinese FDA for treatment of lung cancer in 
human patients (Han et al., 2011).  
Despite successful development of these drugs for 
treatment of human cancers, the survival beneficial 
effects, in general, are rather modest for most 
cancer types. A majority of cancer patients show 
intrinsic resistance toward these antiangiogenic 
drugs (Cao and Langer, 2008, 2010). For those 
patients who initially respond to antiangiogenic 
drugs can also develop evasive refractoriness. 
Additionally, antiangiogenic drugs also produce 
various side effects in cancer patients. Given the 
essential roles of VEGF in regulation of human 
physiology, it is perhaps not unexpected to observe 
broad side effects of anti-VEGF-based 
antiangiogenic drugs in human patients. 
Lymphangiogenic factors and 
therapeutic targets 
Tumor-produced angiogenic factors not only 
stimulate angiogenesis, but often induce 
lymphangiogenesis, which significantly contribute 
to lymph node metastasis (Cao, 2005). Similar to 
blood vessel angiogenesis, tumor 
lymphangiogenesis is also regulated by multiple 
growth factors. Members in the VEGF, FGF, 
PDGF, Ang, HGF, and IGF families have been 
found to actively participate in regulation of 
lymphangiogenesis (Cao, 2005). Moreover, these 
factors induce intra- and peri-tumoral 
lymphangiogenesis that facilitate lymphatic 
metastasis. Among these known lymphangiogenic 
factors, the VEGF-C-VEGFR3 signaling system is 
probably the most well characterized signaling 
pathway in regulation of physiological and 
pathological lymphangiogenesis (Adams and 
Alitalo, 2007; Stacker et al., 2002). VEGFR3 seems 
to be exclusively expressed on lymphatic 
endothelial cells although it is also found in 
angiogenic endothelial cells (Tammela et al., 2008). 
Several lymphangiogenic factors indirectly induce 
lymphangiogenesis through activation of the 
VEGF-C-VEGFR3 signaling system. This indirect 
regulatory mechanism occurs at both VEGF-C 
ligand and VEGFR3 receptor levels at which other 
factors often upregulate expression of these two 
signaling molecules. Notably, the VEGFR3-
mediated lymphatic endothelial tip cell formation is 
probably essential for other lymphangiogenic 
factor-induced lymphangiogenesis. For example, 
FGF-2-induced lymphangiogenesis requires the 
VEGFR3 signaling system for sprouting and 
inhibition VEGFR3 completely ablates FGF-2-
induced lymphangiogenesis (Cao et al., 2012). 
Given the essential role of lymphangiogenesis in 
cancer metastasis, inhibition of lymphangiogenesis 
would in principle be a valid approach for anti-
metastatic cancer therapy. However, development 
of drugs to block cancer metastasis for clinical use 
remains a challenging issue and pharmaceutical 
companies remain reluctant to pursue this avenue. 
Mechanistic challenges of 
antiangiogenic cancer therapy 
The initial antiangiogenic concept for treatment of 
cancer raised by Judah Folkman has led to 
successful development of antiangiogenic drugs for 
treatment of various human cancers. Despite the 
fact that the growth of all solid tumors is dependent 
on angiogenesis, the response rate of antiangiogenic 
therapy in human cancer patients is rather modest 
(Cao and Langer, 2010; Kerbel, 2008). In most 
types of cancers, antiangiogenic drugs are delivered 
together with chemotherapeutics or in combination 
with other therapeutic modalities and 
antiangiogenic monotherapy produce insignificant 
improvement of patient survivals. This clinical 
finding is in marked contrast to the treatment 
regimen in preclinical tumor models in which most 
antiangiogenic agents show potent antitumor effects 
when delivered as a single agent. Why would 
human and mouse tumors respond so differently to 
the same drug (Cao, 2011)? This important question 
remains unresolved at this time of writing. One of 
challenging issues of translating preclinical findings 
into clinical practice is the relevance of preclinical 
mouse tumor models to human patients. In mouse 
tumor models, we often use genetically identical 
mice to study the effect of a given antiangiogenic 
agent whereas each human cancer patient carries 
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genetic information that is different from others. 
Tumors in human patients contain different 
mutations of crucial genes related to cell growth 
and oncogenesis whereas mouse tumors are often 
identical from the same cell line. Human cancers 
are treated at different stages of malignant 
progression and mouse tumors are often treated at 
the same time and similar size during cancer 
development. Importantly, in mouse tumor models 
therapeutic efficacy of antiangiogenic drugs is 
assessed by measuring tumor size and beneficial 
effects of antiangiogenic therapy are often 
determined based on survival improvement. During 
clinical practice, it is increasingly noticed that 
tumor size cannot be used as a reliable surrogate 
marker to predict survival benefits and 
antiangiogenic therapy. Another important issue is 
the mechanism that underlies combination therapy, 
which remains unknown.  
A couple of hypotheses have been proposed to 
explain therapeutic benefits underlying the 
combination of antiangiogenic drugs with 
chemotherapeutics.  
Anti-antiangiogenic drug-induced vascular 
normalization modulates chemotherapeutic delivery 
in tumor tissues offers an attractive mechanism for 
explaining the beneficial effects of combination 
therapy (Jain, 2005).  
Despite some interesting findings in mouse tumor 
model, the vascular normalization concept needs to 
be validated in human cancer patients (Van der 
Veldt et al., 2012). Another interesting concept is 
that antiangiogenic drugs significantly reduce 
chemotherapy-related toxicity in cancer hosts 
(Zhang et al., 2011).  
Again, this interesting concept warrants clinical 
validation. Taken together, the mechanisms by 
which antiangiogenic drugs improve survivals of 
cancer patients remains an enigma despite these 
drugs suppress tumor angiogenesis. Future 
preclinical and clinical studies should focus on 
mechanisms that underlie clinical benefits of these 
drugs in cancer patients. 
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